Scholarlink

Background <p>Cancer patients have an increased risk for cardiovascular diseases (CVDs). Conflicting information exists regarding whether cancer treatment with immune checkpoint inhibitors (ICIs) itself increases the risk for CVDs. We therefore assessed the incidence of major adverse cardiovascular events (MACE) in cancer patients treated with versus without ICIs.</p> Methods <p>One hundred fifty-eight and 163 cancer patients, treated with and without ICIs respectively, were compared. The primary endpoint was the incidence of MACE, defined as acute coronary syndrome, ischemic stroke, transient ischemic attack, new or worsening coronary artery disease or peripheral arterial occlusive disease, or cardiovascular death. We used Cox proportional hazard models and competing risk models (death), adjusted for age, sex and comorbidities (Charlson Comorbidity index, CCI) to investigate the cause-specific association between ICI-treatment and MACE.</p> Results <p>Over a median follow-up of 30.6&#xa0;months, 37 MACE occurred. The overall incidence of MACE was 14.0% in patients with and 9.3% in patients without ICI-treatment. In the multivariate analysis CCI was significantly associated with MACE (HR 1.19, 95% CI [1.03, 1.37]), whereas no association was found for ICI-treatment (HR 1.12, 95% CI [0.56, 2.22]). Competing risk analysis showed no treatment associations. CCI was associated with non-cardiovascular mortality.</p> Conclusions <p>We did not observe statistical evidence of an association between ICI treatment and MACE. There is evidence that a higher comorbidity burden is associated with MACE. Comorbidities are clearly associated with non-cardiovascular mortality in cancer patients. Further prospective studies are required to investigate whether treating comorbidities and optimizing cardiovascular risk factors result in improved outcomes among cancer patients.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between comorbidities and major adverse cardiovascular events in patients undergoing immune checkpoint blockade

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月27日

查看全文
  • Eveline Daetwyler,
  • Annaïse Jauch,
  • Núria Aeschlimann,
  • Nikki Rommers,
  • Benjamin Kasenda,
  • Alfred Zippelius,
  • Gabriela M. Kuster

摘要

Background

Cancer patients have an increased risk for cardiovascular diseases (CVDs). Conflicting information exists regarding whether cancer treatment with immune checkpoint inhibitors (ICIs) itself increases the risk for CVDs. We therefore assessed the incidence of major adverse cardiovascular events (MACE) in cancer patients treated with versus without ICIs.

Methods

One hundred fifty-eight and 163 cancer patients, treated with and without ICIs respectively, were compared. The primary endpoint was the incidence of MACE, defined as acute coronary syndrome, ischemic stroke, transient ischemic attack, new or worsening coronary artery disease or peripheral arterial occlusive disease, or cardiovascular death. We used Cox proportional hazard models and competing risk models (death), adjusted for age, sex and comorbidities (Charlson Comorbidity index, CCI) to investigate the cause-specific association between ICI-treatment and MACE.

Results

Over a median follow-up of 30.6 months, 37 MACE occurred. The overall incidence of MACE was 14.0% in patients with and 9.3% in patients without ICI-treatment. In the multivariate analysis CCI was significantly associated with MACE (HR 1.19, 95% CI [1.03, 1.37]), whereas no association was found for ICI-treatment (HR 1.12, 95% CI [0.56, 2.22]). Competing risk analysis showed no treatment associations. CCI was associated with non-cardiovascular mortality.

Conclusions

We did not observe statistical evidence of an association between ICI treatment and MACE. There is evidence that a higher comorbidity burden is associated with MACE. Comorbidities are clearly associated with non-cardiovascular mortality in cancer patients. Further prospective studies are required to investigate whether treating comorbidities and optimizing cardiovascular risk factors result in improved outcomes among cancer patients.

Graphical Abstract